Nanolek Launches Russia’s First Full-Cycle Production of Human Papillomavirus (HPV) Vaccine
The biopharmaceutical company Nanolek, with the support of the...
Microgen has registered a new vaccine for children against tick-borne encephalitis in Belarus
The children's vaccine Encevir Neo for the prevention of...
Solopharm has launched a new plant for the production of soft dosage forms
Solopharm, one of the leading pharmaceutical manufacturers in Russia,...
Production of Insulins under the GEROPHARM Technology Will Be Launched in Venezuela in 2025
On 7 November 2024, Dmitriy Chernyshenko, Deputy Prime Minister...
ChemRar invests one billion rubles in a new plant for the production of pharmaceutical substances in Khimki
Construction is expected to be fully completed by the end of 2024, with full production start-up scheduled for Q1-Q2 2025.
Good AI Practice: EMA and FDA Establish 10 Global Principles
Global regulators are setting a unified standard for the...
Eli Lilly and NVIDIA Open $1B AI R&D Center for Molecule Generation
Eli Lilly and NVIDIA have announced a major partnership...
Obesity Pill Battle: Lilly’s Chemistry vs. Novo’s Peptides
2026 marks not just the arrival of new therapies,...
OpenAI Enters Healthcare Market with ChatGPT Health and Enterprise Clinical Platform
OpenAI has officially announced its expansion into the healthcare...
Gennady Schweigert and Pavel Mileiko acquire 50% stake in Nanolek LLC
Nanolek LLC informs about changes in the ownership structure:...
Good AI Practice: EMA and FDA Establish 10 Global Principles
Global regulators are setting a unified standard for the...
Automated Blocking of Banned Vet Drugs in Russia May Launch in 2026
The Center for Research in Perspective Technologies (CRPT) and the regulator Rosselkhoznadzor have announced the creation of a mechanism that will eliminate the human factor in removing dangerous animal medicines from circulation.
Sale of Drugs in Foreign Packaging Allowed in Russia Until End of 2027
The Government of the Russian Federation has decided to...
Over 21,500 Illegal Online Pharmacies Blocked in 2025 Following Roszdravnadzor
The Russian healthcare regulator has summarized the results of...
Russia Updates Pharma Licensing: New Timelines and Remote Inspections
The Russian Government has approved a new resolution updating...
Good AI Practice: EMA and FDA Establish 10 Global Principles
Global regulators are setting a unified standard for the...
Eli Lilly and NVIDIA Open $1B AI R&D Center for Molecule Generation
Eli Lilly and NVIDIA have announced a major partnership...
OpenAI Enters Healthcare Market with ChatGPT Health and Enterprise Clinical Platform
OpenAI has officially announced its expansion into the healthcare...
OSE Immunotherapeutics collaborates with Microsoft to further develop its digital infrastructures
OSE Immunotherapeutics SA today announces that the Company is...
AI specialist Insilico raises $60m to launch AI-powered drug discovery robotics laboratory
Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug...
Nanolek Launches Russia’s First Full-Cycle Production of Human Papillomavirus (HPV) Vaccine
The biopharmaceutical company Nanolek, with the support of the...
Microgen has registered a new vaccine for children against tick-borne encephalitis in Belarus
The children's vaccine Encevir Neo for the prevention of...
Solopharm has launched a new plant for the production of soft dosage forms
Solopharm, one of the leading pharmaceutical manufacturers in Russia,...
Production of Insulins under the GEROPHARM Technology Will Be Launched in Venezuela in 2025
On 7 November 2024, Dmitriy Chernyshenko, Deputy Prime Minister...
ChemRar invests one billion rubles in a new plant for the production of pharmaceutical substances in Khimki
Construction is expected to be fully completed by the end of 2024, with full production start-up scheduled for Q1-Q2 2025.
Good AI Practice: EMA and FDA Establish 10 Global Principles
Global regulators are setting a unified standard for the...
Eli Lilly and NVIDIA Open $1B AI R&D Center for Molecule Generation
Eli Lilly and NVIDIA have announced a major partnership...
Obesity Pill Battle: Lilly’s Chemistry vs. Novo’s Peptides
2026 marks not just the arrival of new therapies,...
OpenAI Enters Healthcare Market with ChatGPT Health and Enterprise Clinical Platform
OpenAI has officially announced its expansion into the healthcare...
Gennady Schweigert and Pavel Mileiko acquire 50% stake in Nanolek LLC
Nanolek LLC informs about changes in the ownership structure:...
Good AI Practice: EMA and FDA Establish 10 Global Principles
Global regulators are setting a unified standard for the...
Automated Blocking of Banned Vet Drugs in Russia May Launch in 2026
The Center for Research in Perspective Technologies (CRPT) and the regulator Rosselkhoznadzor have announced the creation of a mechanism that will eliminate the human factor in removing dangerous animal medicines from circulation.
Sale of Drugs in Foreign Packaging Allowed in Russia Until End of 2027
The Government of the Russian Federation has decided to...
Over 21,500 Illegal Online Pharmacies Blocked in 2025 Following Roszdravnadzor
The Russian healthcare regulator has summarized the results of...
Russia Updates Pharma Licensing: New Timelines and Remote Inspections
The Russian Government has approved a new resolution updating...
Good AI Practice: EMA and FDA Establish 10 Global Principles
Global regulators are setting a unified standard for the...
Eli Lilly and NVIDIA Open $1B AI R&D Center for Molecule Generation
Eli Lilly and NVIDIA have announced a major partnership...
OpenAI Enters Healthcare Market with ChatGPT Health and Enterprise Clinical Platform
OpenAI has officially announced its expansion into the healthcare...
OSE Immunotherapeutics collaborates with Microsoft to further develop its digital infrastructures
OSE Immunotherapeutics SA today announces that the Company is...
AI specialist Insilico raises $60m to launch AI-powered drug discovery robotics laboratory
Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug...
PHARMPROM is a premier digital resource for the pharmaceutical sector, combining breaking news, deep insights, and key market events. We cover the entire product lifecycle—from R&D and manufacturing to distribution—in strict accordance with Good Pharmaceutical Practices (GxP).
Disclaimer All content on pharmprom.net is for informational purposes only and does not constitute medical advice. The materials are intended exclusively for industry professionals and are not addressed to the general public.
Headlines
Event Marketing in Pharma: Turning Digital Reputation into Real Contracts
Despite the total digitalization of business processes, the pharmaceutical...
“Golden” Potency: 2.4 Billion Rubles Wasted on “Russian Viagra” Project
A scandal in the state pharmaceutical sector: The Accounts...
Eurasian Pharma Register Cannot Be Used to Disqualify Tender Bids
A significant ruling for Russian pharmaceutical distributors: The Arbitration...
Good AI Practice: EMA and FDA Establish 10 Global Principles
Global regulators are setting a unified standard for the...
Newsletter
Get important news delivered directly to your inbox and stay connected!
© PHARMPROM 2026